VYNE
Companies
NASDAQ
Vyne Therapeutics Inc.
Health Care
$0.94
-$2.39 (-71.76%)
Price Chart
Overview
About VYNE
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Market Cap
$32.7M
Volume
215.4K
Avg. Volume
151.1K
P/E Ratio
-1.7356322
Dividend Yield
0.00%
Employees
19.0
Company Information
Risk & Correlation Analysis
Market Correlation
1.22
Moderate Correlation
Volatility
High (0.81)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, VYNE shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$32.7M
Volume215.4K
P/E Ratio-1.74
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 6, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025